Hilton, J. F., Ott, P. A., Hansen, A. R., Li, Z., Mathew, M., Messina, C. H., Dave, V., Ji, X., Karpinich, N. O., Hirschfeld, S., Ballas, M., & Zandberg, D. P. (2024). INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 73(3). https://doi.org/10.1007/s00262-023-03623-z

Gartrell, R. D., Blake, Z., Rizk, E. M., Perez-Lorenzo, R., Weisberg, S. P., Simoes, I., Esancy, C., Fu, Y., Davari, D. R., Barker, L., Finkel, G., Mondal, M., Minns, H. E., Wang, S. W., Fullerton, B. T., Lozano, F., Chiuzan, C., Horst, B., & Saenger, Y. M. (2022). Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma. Cancer Immunology, Immunotherapy, 71(8), 1837–1849. https://doi.org/10.1007/s00262-021-03088-y